Capivasertib is named as a drug or biological intervention in 12 clinical trials in our USA, UK, China and India trial registers, 3 of which are recruiting. Lead sponsors include AstraZeneca (8), Stemline Therapeutics, Inc. (1) and Relay Therapeutics, Inc. (1). Registered phases: Phase 3, Phase 1/2 and Phase 1. Conditions studied include Breast Cancer; Triple Negative Breast Neoplasms; Locally Advanced (Inoperable) or Metastatic Breast Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Breast Cancer | 3 |
| Triple Negative Breast Neoplasms | 2 |
| Locally Advanced (Inoperable) or Metastatic Breast Cancer | 2 |
| Prostate Cancer | 1 |
| Metastatic Breast Cancer | 1 |
| Hormone-Sensitive Prostate Cancer | 1 |
| PIK3CA Mutation | 1 |
| HER2- Negative Breast Cancer | 1 |
| Hormone Receptor Positive Tumor | 1 |
| Melanoma (Skin Cancer) | 1 |
| HER2-low Hormone Receptor Positive Breast Cancer | 1 |
| Moderate Hepatic Impairment | 1 |
| Lung Cancer (NSCLC) | 1 |
| Lung Cancer (Non-Small Cell) | 1 |
| Advanced Non-small-cell Lung Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 8 |
| Stemline Therapeutics, Inc. | 1 |
| Relay Therapeutics, Inc. | 1 |
| Aminex Therapeutics, Inc. | 1 |
| Shanxi Province Cancer Hospital | 1 |
| Register | Capivasertib trials |
|---|---|
| Clinical trials in USA | 10 |
| Clinical trials in UK | 8 |
| Clinical trials in China | 7 |
| Clinical trials in India | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Capivasertib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Capivasertib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.